JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose

* Asian subjects aged 20 years of age or older with dissatisfaction of their aesthetic appearance due to structural features of their nose * Subjects who, in the opinion of the Investigator, can achieve a clinically meaningful aesthetic correction of their nose with VOLUMA® treatment

* -Subjects requiring filler treatment in or around the tip of the nose or between the eyebrows (glabellar region) to achieve a good aesthetic outcome * prior nasal surgery, including grafts, implants or filler injection to the nose area * Subjects with a history of sinusitis or rhinitis * Subjects unlikely to achieve a meaningful aesthetic result with the prescribed dosage regimen of the study product. * Subjects receiving botulinum toxin treatment for any indication within 3 months of the study or planning to receive botulinum toxin during the study * Subjects who have previously received aesthetic treatment in the forehead, glabellar, and/or nose area with any dermal filler * Subjects with a history of any significant adverse events caused by dermal fillers * Subjects with a history of allergic responses to lidocaine or fillers * Subjects who are pregnant or breastfeeding or wish to become pregnant during the study * Subjects of child-bearing age who are not prepared to practice an adequate form of contraception during the course of the study * Subjects with traumatic scars in the treatment area or a history of active inflammation, infection, cancerous lesion, or an unhealed wound in the treatment area * Subjects requiring dental or oral surgery, including dental implants, during the study period * Subjects with a history of bleeding disorders * Subjects who are smokers * Subjects using blood thinning products within 10 days of the screening visit * Subjects with a history of connective tissue disease (e.g., rheumatoid arthritis, lupus, scleroderma, etc) causing skin scarring * Subjects with a history of untreated epilepsy or other significant medical conditions * Subjects with a history of alcoholism or drug abuse of dependence * Subjects participating or likely to participate in another clinical trial within 30 days of screening or during the 1 year period of the study * Subjects with any other medical condition, which in the opinion of the Investigator, might compromise the subject's ability to tolerate the injection procedure or comply with requirements of the study